Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • In Brief
  • Published:

Urological cancer

Overcoming bladder cancer chemoresistance

Nature Reviews Clinical Oncology volume 12, page 64 (2015)Cite this article

Subjects

Access through your institution
Buy or subscribe

Activation of bladder cancer stem cells (CSCs) can drive progressive resistance to chemotherapy. Cytotoxic therapy is initially effective in debulking tumours, but it has now been shown that apoptosis promotes release of prostaglandin E2 (PGE2), which stimulates quiescent CSCs to divide, proliferate and repopulate the tumour. Inhibition of PGE2 signalling blocks CSC repopulation, and attenuates progressive chemoresistance in xenograft tumours, and might represent a new treatment paradigm for patients with bladder cancer.

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Kurtova, A. V. et al. Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance. Nature 10.1038/nature14034

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Overcoming bladder cancer chemoresistance. Nat Rev Clin Oncol 12, 64 (2015). https://doi.org/10.1038/nrclinonc.2014.232

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.232

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer